首页> 外文期刊>PLoS One >Digitalization of adverse event management in oncology to improve treatment outcome—A prospective study protocol
【24h】

Digitalization of adverse event management in oncology to improve treatment outcome—A prospective study protocol

机译:肿瘤中不良事件管理的数字化改善治疗结果 - 一种预期研究协议

获取原文
           

摘要

The occurrence of adverse events frequently accompanies tumor treatments. Side effects should be detected and treated as soon as possible to maintain the best possible treatment outcome. Besides the standard reporting system Common Terminology Criteria for Adverse Events (CTCAE), physicians have recognized the potential of patient-reporting systems. These are based on a more subjective description of current patient reporting symptoms. Patient-reported symptoms are essential to define the impact of a given treatment on the quality of life and the patient’s wellbeing. They also act against an underreporting of side effects which are paramount to define the actual value of a treatment for the individual patient. Here, we present a study protocol for a clinical trial that assesses the potential of a smartphone application for CTCAE conform symptom reporting and tracking that is adjusted to the standard clinical reporting system rather than symptom oriented descriptive trial tools. The presented study will be implemented in two parts, both lasting over six months. The first part will assess the feasibility of the application with 30 patients non-randomly divided into three equally-sized age groups (75years). In the second part 36 other patients will be randomly assigned to two groups, one reporting using the smartphone and one not. This prospective second part will compare the impact of smartphone reported adverse events regarding applied therapy doses and quality of life to those of patients receiving standard care. We aim for early detection and treatment of adverse events in oncological treatment to improve patients’ safety and outcomes. For this purpose, we will capture frequent adverse events of chemotherapies, immunotherapies, or other targeted therapies with our smartphone application. The presented trial is registered at the U.S. National Library of Medicine ClinicalTrials.gov ( {"type":"clinical-trial","attrs":{"text":"NCT04493450","term_id":"NCT04493450"}} NCT04493450 ) on July 30, 2020.
机译:不良事件的发生经常伴随肿瘤治疗。应尽快检测和处理副作用以保持最佳的治疗结果。除了标准报告系统的常见术语标准外,不良事件(CTCAE),医生已经认识到患者报告系统的潜力。这些基于当前患者报告症状的更具主观描述。患者报告的症状对于定义给定治疗对生命质量和患者的幸福性的影响至关重要。它们还针对副作用的爆向,这是为单个患者定义治疗的实际值的副作用。在这里,我们提出了一种用于临床试验的研究方案,可评估CTCAE智能手机应用程序的潜力符合标准临床报告系统的症状报告和跟踪,而不是症状导向的描述性试验工具。本研究将在两部分实施,持续六个月。第一部分将评估应用30名患者的应用的可行性,无随机分为三个同等大小的年龄组(75年)。在第二部分36中,其他患者将随机分配给两组,一个报告使用智能手机和一个。该潜在的第二部分将比较智能手机对接受标准护理患者的应用治疗剂量和生活质量的不良事件的影响。我们的目标是早期检测和治疗肿瘤治疗不良事件,以改善患者的安全和结果。为此目的,我们将捕获使用智能手机应用程序的化学疗法,免疫疗法或其他有针对性的疗法的频繁不良事件。本试验在美国国家医学图书馆注册ClinicalTrials.gov({“类型”:“临床试验”,“attrs”:{“text”:“nct04493450”,“term_id”:“nct04493450”}} NCT04493450 )2020年7月30日。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号